On our screens:Stocks with no debt
The financials
Bio-Rad Laboratories, Inc. by the numbers
Bio-Rad Laboratories, Inc. (BIO) reported revenue of $592M in Q1 2026 (quarter ended Mar 31, 2026), up 1.1% from the same quarter a year earlier. That came with a gross margin of 52% and net loss of $527M. For the full year FY2025, revenue was $2.58B (+0.7% year on year) and net income $760M. Its largest region in Jun 2026 was United States at $256M, 39% of the disclosed total, just ahead of Europe at 35%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $592M | $585M | +1.1% |
| Gross profit | $309M | $306M | +1.1% |
| Operating income | $34M | $24M | +44% |
| Net income | −$527M | $64M | to a loss |
| Diluted EPS | −$19.55 | $2.29 | to a loss |
| Geographic | Revenue | Share |
|---|---|---|
| United States | $256M | 39% |
| Europe | $229M | 35% |
| Asia Pacific | $122M | 19% |
| Americas | $45M | 6.8% |
Business Segments
Revenue split by geographic segment, from SEC XBRL filings.
Latest period: Jun 2026Total $651.0M (+9.9%)
Americas grew +8.3% year on yearUnited States -4.3% year on year
Segment Latestquarter on quarteryear on year
- United States$255.5M$255.5MQoQ +11%year on year -4.3%+11%-4.3%
- Europe$229.2M$229.2MQoQ +11%year on year +5.5%+11%+5.5%
- Asia Pacific$121.8M$121.8MQoQ +10%year on year -3.6%+10%-3.6%
- Americas$44.5M$44.5MQoQ -1.3%year on year +8.3%-1.3%+8.3%
Medical Devices
Ranks #21 of 29 by Smart Score